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Background: The laboratory mouse model is commonly employed to study the pathogenesis of encephalitic
flaviviruses such as Japanese encephalitis virus (JEV). However, it is known that some strains of these viruses do not
elicit a typical mortality dose response curve from this organism after peripheral infection and the reason for it has
not yet been fully understood. It is suggested that induction of more vigorous Type-I IFN (IFN-I) response might
control early virus dissemination following increasing infectious challenge doses of the virus. Thus, the objective of
this study was to examine this suggested role of IFN-I in the mortality of mice infected with various doses of JEV.
Methods: Inbred 129 mice and their IFNAR KO (A129) mice were subcutaneously inoculated with 100, 102, 104 or
106 pfu of JaOArS982 strain of JEV. Mice were weighed daily and observed for clinical signs. Virus titers in the brains
and spleens of JEV-infected mice were determined by plaque forming assays. The upregulated mRNA levels of
genes related to IFN-I response of mice were examined by real-time PCR.
Results: The mortality rates of 129 mice infected with JaOArS982 did not significantly increase despite the increase
in inoculation dose and no significant difference of viral loads was observed between their brains. However, there
was clear elevation of the mRNA levels of interferon regulatory factor (IRF)3, IRF7, IRF9, MDA5 and RIG-I at 24 hours
post-infection depending on the inoculation dose. In A129 mice, length of survival days and the viral loads of
spleen and brain were observed to be inoculation dose-dependent.
Conclusions: From these results, it is suggested that early IFN-I response elicited by high inoculation doses of JEV
provides an anti-viral effect during the early phase of infection. Accordingly, virus replication is counteracted by
IFN-I response at each increasing inoculation dose resulting in the interference of impending severe disease course
or fatal outcome; hence, this might explain the inoculation dose-independent mortality in mice caused by
Japanese encephalitis virus.
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Japanese encephalitis virus (JEV) belonging to the genus
Flavivirus of the family Flaviviridae, is a causative agent
of Japanese encephalitis (JE), an acute central nervous
system (CNS) disease in humans [1]. JE is considered as
one of the most important encephalitic arthropod-borne
diseases. An estimated 3 billion people live in countries* Correspondence: hayasaka@nagasaki-u.ac.jp
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unless otherwise stated.where JE is endemic and 30,000 - 50,000 cases and 10,000 -
15,000 deaths are reported annually [1-3]. However, be-
cause many cases in less well developed countries are
almost certainly unreported, this is likely to be a gross
underestimate of the actual number of cases that either
result in fatality or infection with severe sequelae. Thus, it
is important to understand the mechanism of the develop-
ment of the disease especially in severe cases.
To study the CNS pathology induced by encephalitic
flaviviruses such as JEV and tick-borne encephalitis
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Figure 1 Mortality and viral loads of 129 mice subcutaneously
inoculated with the JaOArS982 strain of JEV. Mortality (A) and
survival (B) rates of mice inoculated with 100, 102, 104 or 106 pfu of
JEV (n=14 per inoculation dose). Mortality rate was recorded 21 days
pi. (C) Infectious virus titers in the brains of mice inoculated with
100, 102, 104 or 106 pfu of the JaOArS982 strain of JEV at 5 and 9
days pi (n=3 per inoculation dose and day of sacrifice). Error bars
represent the standard errors.
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observed in infected mouse brains are similar to those
observed in humans [4-10].
In general, to evaluate the virulence and pathogenicity
of virus infection in a mouse model, lethal dose has been
used as an index and it is believed that an increase in
inoculation dose can cause high mortality. However, it is
known that mice infected peripherally with some strains
of encephalitic flaviviruses do not exhibit a typical mortal-
ity dose response curve. Although this has been reported
since the 1940’s [11], the reason for this apparent dis-
crepancies has until now not been fully understood. We
previously reported that late death following TBEV and
JEV infections appears to be a key feature of inoculation
dose-independent mortality [12,13]. Late death was obser-
ved in mice subcutaneously inoculated with 100 to 106 pfu
of these viruses [12,13]. However, we were not able to fully
elucidate why no significant difference was found between
any of the mortality rates despite the increase in inocula-
tion doses.
Recently, it was suggested that induction of more vig-
orous innate immune response might control early virus
dissemination following increasing infectious challenge
doses of the virus [8,14,15]. Thus, in this study, we focused
on Type-I IFN (IFN-I) response induced at early phase
following extraneural infection and examined its role in
the mortality of mice.
Results
Inoculation dose-independent mortality in inbred 129 mice
subcutaneously infected with JEV
In this study, we used inbred 129 mice to minimize the
influence of the genetic background in each organism.
Following subcutaneous inoculation with JaOArS982
strain of JEV, the mortality rates of infected mice did not
increase significantly with increase in the inoculation
dose (Figure 1A). Survival curves also did not differ
significantly despite the increase in inoculation dose
(Figure 1B). Mice that died exhibited general clinical
signs such as slow movement, ataxia, piloerection, an-
orexia and continuous weight loss after 7–10 days
post-infection (pi), but apparent clinical signs of CNS
diseases such as paralysis were not observed as in our
previous study [13]. The patterns of weight loss and clin-
ical signs were also not significantly different at any
time point between different inoculation doses (data not
shown).
Infectious virus was detectable in the brain tissues at
5 days pi (Figure 1C) but not in the peripheral tissues such
as spleen (data not shown). Of note, at 5 and 9 days pi, no
significant difference of viral loads was observed between
brains from mice that received different doses of the virus
(Figure 1C). These observations suggest that in this mouse
model, mortality is not dependent on the inoculation dose,and that virus infection and replication seems to be being
interfered at early phase before CNS infection.
IFN-I response in the spleen of 129 mice infected with
various doses of JEV
To examine IFN-I response, we first measured the levels
of IFN-α and IFN-β in the serum using some commercial
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all mice infected with various doses of JEV nor in all unin-
fected mice (data not shown). In the spleen, we also tried
to detect and compare the expression levels of IFNs and
IFN-I related proteins by Western blot, however, we failed.
Thus, we next examined the mRNA levels of genes related
to IFN-I response of mice by real-time PCR referred to in
previous studies [12,13,16,17].
At 24 hours pi, the mRNA levels of interferon regula-
tory factor (IRF)3, IRF7, IRF9, MDA5 and RIG-I were
clearly elevated depending on the inoculation dose of
JaOArS982 with 106 pfu per inoculation as the highest
dose (Figure 2A). The mRNA level of PKR, one of ISG
products induced by IFNs, was also increased as the viral
dose was increased (Figure 2A). IFN-α and IFN-β also
tended to elevate in an inoculation dose-dependent
manner, although uninfected mice also exhibited some
upregulation of these IFNs but the differences in the
mRNA levels were not significant (Figure 2A).
At 48 hours pi, the mRNA levels of IRF3 and IRF7 were
elevated depending on the inoculation dose (Figure 2B).
However, the highest levels of MDA5, RIG-I and PKR
were found in 104 pfu-inoculated mice. IRF9 of 106, 104
and 102 pfu-inoculated mice showed similar up-regulated
levels (Figure 2B). IFN-α and IFN-β also tended to elevate
in an inoculation dose-dependent manner, although the
differences in the mRNA levels were not significant
(Figure 2B).
At 72 hours pi, the level of IRF7 was higher in 104and
102 pfu-inoculated mice compared with other mice groups
(Figure 2C). IRF9, MDA5 and RIG-I showed highest levels
in 102 pfu-inoculated mice compared with other mice
groups (Figure 2C). IRF3, PKR, IFN-α and IFN-β also
tended to be more elevated in 102 pfu-inoculated mice,
although the differences in the mRNA levels were not
significant (Figure 2C).
These results suggested that the mRNA levels of IFN-I
related genes can elevate as the dose of inoculated JEV
is increased and that the peaks shift to lower inoculation
doses as time passes by.
Inoculation dose-dependent mortality in IFNAR KO mice
infected with JEV
To confirm whether IFN-I response is related to the
dose-independent mortality, we next inoculated sub-
cutaneously different doses of JaOArS982 in IFNAR
KO (A129) mice and observed their mortality. Although a
total of 90% (100 pfu) or 100% (102, 104 and 106 pfu)
of JaOArS982-inoculated mice died during the obser-
vation period (Figure 3A), the length of survival hours
were clearly inoculation dose-dependent (Figure 3B).
Mice died by 64, 80, 96 and 120 hours pi following
106, 104, 102 and100 pfu inoculation doses, respectively
(Figure 3B).In the spleens, infectious viruses were detected initially
at 24 h pi in 106 and 104 pfu-inoculated mice, at 48 h in
102 pfu-inoculated mice, and at 72 h pi in 100 pfu-
inoculated mice, and the viral loads changed in a dose-
dependent manner through time (Figure 3C). In the
brains, infectious viruses were detected initially at 24 h pi
in 106 pfu-inoculated mice, at 48 h pi in 104 pfu-inocu-
lated mice, and at 72 h pi in 102 and 100 pfu-inoculated
mice (Figure 3D). Thus, virus infection and replication in
the peripheral tissues and brains are clearly inoculation
dose-dependent in A129 mice.
Discussion
In this study, we confirmed that mouse mortality is not
dependent on the inoculation dose of JEV, that the increase
in the mRNA levels of IFN-I related genes in mouse is
suggested to be related to the increase of the dose of inoc-
ulated JEV, and that when IFN receptor is incapacitated
during infection an inoculation dose-dependent mortality
can occur in a mouse. Taken together, these suggest that
IFN-I response affects the dose-independent mortality in
a mouse model.
In our preliminary experiments, we intravenously
injected constant amount of Poly (I:C) (a potent IFN in-
ducer) or exogenous IFNs in mice following JEV infection
to examine whether this treatment could provide protec-
tion in JEV-infected mice at lower inoculation dose but
not at a higher dose. However, apparent protective effect
on mortality by this treatment was not observed, and
hence dose-independent mortality was not restored (data
not shown). It could be due to technical problem that pre-
vented IFN effects to reach local sites of infected tissues,
because apparent IFN-I induction was not confirmed in
the serum of mice injected with either inoculum (data not
shown). However, this kind of approach is important
because it may be able to give certain clues for elucidating
further the mechanism on dose-independent mortality
and thus further improvement of experimental design is
required.
IFN-I response of JEV infected mice was initially exam-
ined by determining the levels of IFN-α and IFN-β in the
serum through ELISA, but our attempt failed even in the
mice that showed high mRNA levels of IFN-α and IFN-β
in the spleen, e.g. those that received 106 pfu inoculation
at 24 hours pi and 102 pfu inoculation at 72 hours pi. It
could be due to technical difficulty. Therefore, the mRNA
levels which were easier to detect by quantitative real-time
RT-PCR were determined instead.
We examined the levels for IRF3, IRF7, IRF9, MDA5,
RIG-I and PKR. IRFs play central roles in the induction of
IFN-I at the gene transcriptional level [18]. IRF3 and IRF7
have been implicated as positive regulators of IFN-I gene
expression induced by virus infections [18,19], whereas
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Figure 2 (See legend on next page.)
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Figure 2 mRNA levels of IFN-I related genes of 129 mice subcutaneously inoculated with the JaOArS982 strain of JEV. mRNA levels were
quantified by real-time PCR in the spleens of 129 mice inoculated with 100, 102, 104 or 106 pfu of JEV at 24 (A), 48 (B) 72 (C) hours pi and of
uninfected 129 mice (n=3 per group). Uninfected mice show the same data in A, B, and C. Error bars represent the standard errors. P values were
calculated by ANOVA. Asterisk indicates the pair that shows significant difference by Tukey’s Multiple Comparison Test.
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tion of the IRF7 gene [18]. MDA5 and RIG-I function as
cytoplasmic sensors of pathogen-associated molecular
patterns within viral RNA and their expression is greatly
increased with IFN-I exposure following virus infection
[20]. They trigger the signal pathway of IRF3 and IRF7
[18,19]. PKR, an IFN-inducible gene product, binds to
viral double-stranded RNA and halts protein synthesis by
phosphorylating translation initiation factor eIF2 [21]. It
plays an important role for the IFN-I induction, and its
activation accompanies IRF3 activation [22,23]. The up-
regulation of the mRNA of these IFN-I related genes were
observed in the present study in JEV infected mice and
these reflected IFN response. A component or compo-
nents of this response could have been affected following
JEV infection at very high dose leading to a dose inde-
pendent mortality.
Interestingly, it was observed that mRNA levels of







































































Figure 3 Mortality and viral loads of A129 mice subcutaneously inocu
(B) rates of mice inoculated with 100, 102, 104 or 106 pfu of JEV (n=10 per
brains (D) of mice inoculated with 100, 102, 104 or 106 pfu of the JaOArS98
represent the standard errors. P values were calculated by ANOVA at eachsomehow higher than those of 102 and 100 pfu-inocu-
lated mice at 24 and 48 hours pi (Figure 2). Although
One-way analysis of variance and Tukey’s Multiple
Comparison Test used in this study showed no signifi-
cant differences between them, these observations raised
the possibility that low-dose inoculation with JEV might
induce suppressive effects on IFN-I mRNA levels at
early phase of infection. Further investigations will be
required to elucidate this phenomenon.
In our previous and preliminary studies, we tried to
detect mRNA of inflammatory genes including IFNs and
their associated genes in the brains of JEV-infected mice.
However, these mRNA were detected only after 5 days
pi and the levels were not significantly different between
mice inoculated with different doses. These observations
showed patterns of viral loads similar to those shown in
Figure 1. Clinical signs in fatal cases were observed after
7–10 days pi, but apparent CNS disease such as paralysis















lated with the JaOArS982 strain of JEV. Mortality (A) and survival
group). p: Log-lank test. Infectious virus titers in the spleens (C) and
2 strain of JEV at 24, 48 and 72 hours pi (n=3 per group). Error bars
time point.
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oculation doses. In our JEV-infected mouse model, main
pathological changes and neuronal damage were observed
in brain cortex [13]. The lesions seem to be related to
memory deficiency and mental retardation but not paraly-
sis and movement disorder. Thus, it was quite difficult to
observe the CNS signs in JEV-infected mice, although
lethal encephalitis was observed in dead mice. Encephalitis
was a result of neuronal infection and subsequent inflam-
matory response. Systemic IFN-I response at early phase
of infection appears to affect to viral CNS entry and neur-
onal infection. Therefore, we suggest that interference of
inoculation dose-dependence by IFNs occurred in periph-
eral tissues, and thus subsequent neuronal infection and
inflammatory responses including IFNs in the brains were
not different between various inoculation doses.
We previously suggested that immunopathogenic re-
sponses in addition to high CNS infection contribute to
the severe prognoses and we observed variable immune
response in individual mouse infected with JEV or TBEV
[13,24]. These data raise the possibility that there may
be a variety of acquired immune response, e. g. specific
T cell clones affecting either protective or pathogenetic
functions in dying and recovering mice. Furthermore,
we propose that the mortality following extraneural in-
fection in mice does not simply represent neuroinvasive-
ness and thus it is difficult to compare pathogenesis by
the lethal doses after peripheral inoculation in mouse
model. To understand the pathogenic mechanism of
flavivirus encephalitis, further elucidation of IFN-response,
immunopathological effect, and their correlation will be
an important priority to develop effective treatment strat-
egies for flavivirus encephalitis.
Conclusion
In conclusion, it is suggested that early IFN-I response of
normal mice after receiving high inoculation doses of JEV
provides an anti-viral effect during the early phase of infec-
tion. Virus replication is counteracted by IFN-I response at
each increasing inoculation dose resulting in the interfer-
ence of impending severe disease course or fatal outcome
and this might explain the inoculation dose-independent
mortality in mice caused by Japanese encephalitis virus.
Methods
Virus and cells
Stocks of JaOArS982 strain of JEV were obtained from cell
culture medium of infected BHK cells [25]. The BHK cells
were maintained in Eagle’s Minimal Essential Medium
(EMEM) containing 10% fetal calf serum.
Mice
Inbred 129 mice were provided by RIKEN BRC through
the National Bio-Resource Project of the MEXT, Japan.A129 mice were purchased from B & K Universal lim-
ited. These mice were mated in the facility of Nagasaki
University. Five to six week old mice [129 (n=14) and
A129 (n=10)] were subcutaneously inoculated with 100,
102, 104 or 106 pfu of JaOArS982. Mice were weighed
daily and observed for clinical signs for 21 days. The ex-
perimental protocols were approved by the Animal Care
and Use Committee of the Nagasaki University (approval
number: 091130-2-7 / 0912080807–7).
Titration of virus in tissues
Mice subcutaneously inoculated with 100, 102, 104 or 106
pfu of JaOArS982 (n=3 for each dose) were euthanized on
days 5 and 9 pi, and spleens and brain cortices were
collected. Individual organ was homogenized and virus
titers (expressed as pfu/g tissue) were determined by
plaque forming assay in BHK cells [12,13].
Quantitative estimation of the upregulation of IFN-I related
genes in spleens
Mice subcutaneously inoculated with 100, 102, 104 or
106 pfu of JaOArS982 were euthanized, and spleens were
collected. Experiments were carried out three times and
data presented were pool of these experiments (thus a
total of n=3 per dose). Total RNA was extracted and the
mRNA levels of IRF3, IRF7, IRF9, MDA5, RIG-I, PKR,
IFN-α and IFN-β were measured by real time-PCR as
demonstrated previously [16].
Statistical analyses
Statistical analyses were performed by using GraphPad
Prism 5 (GraphPad Software, Inc). One-way analysis of
variance was used to assess the significant differences
between viral loads and between mRNA levels of genes.
Tukey’s Multiple Comparison Test of post hoc analysis
was used to further compare which pairs were signifi-
cantly different. However, GraphPad Prism 5 did not
show actual p values in this test but only indicated
whether P < 0.05 or not. To assess the significant differ-
ences between four groups (100, 102, 104 or 106 pfu ) of
JEV-infected mice, survival analysis was performed by
Log-rank (Mantel-Cox) test.
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